Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.
Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
European Medicines Agency Grants Orphan Drug Designation to Tinengotinib for Biliary Tract Cancer
FDA Awards Orphan Drug Designation to Cambritaxestat for Pancreatic Cancer
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer
Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care
McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology